Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia that files as a foreign private issuer with the U.S. Securities and Exchange Commission. Its SEC filings, primarily on Form 6-K, provide insight into the company’s healthcare and wellness strategy, financing arrangements, governance changes and interim financial results.
Recent Form 6-K reports describe a convertible promissory note purchase agreement with an institutional investor, conversions of portions of the note into ordinary shares, and letter agreements that modify conversion timing and terms. Other filings detail a securities purchase agreement with Streeterville Capital, LLC for a warrant exercisable into newly issued ordinary shares, along with subsequent amendments that adjust the warrant exercise price and forced exercise thresholds. These documents help investors understand EUDA’s capital structure, dilution mechanisms and use of shelf registration on Form F-3.
EUDA’s 6-K filings also cover matters such as director resignations and appointments, including the addition of an independent director with ties to a key stem cell business partner, and the furnishing of unaudited condensed consolidated financial statements and operating and financial review for interim periods. Together, these filings outline both corporate governance and financial reporting aspects of the company.
On Stock Titan’s EUDA filings page, users can access these SEC submissions as they are made available through EDGAR, alongside AI-powered summaries that explain the key terms, context and potential implications of each document. This includes highlighting material terms in financing agreements, noting changes in board composition and pointing to where investors can find financial statements and narrative discussion of EUDA’s performance and prospects within its non-invasive healthcare, longevity and property management activities.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.
EUDA Health Holdings Ltd Chief Financial Officer Tay Whye Shin has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The filing establishes this officer’s reporting status under SEC rules but does not report any stock transactions.
EUDA Health Holdings Ltd director Liew Kwong Yeow filed an initial ownership report showing direct holdings of 3,000 Ordinary Shares. This Form 3 does not report any recent buy or sell transactions; it simply establishes his current equity stake in the company.
EUDA Health Holdings Ltd director Lew Chern Yong has filed a Form 3, which records his status as an insider of the company. The provided data does not list any equity transactions or derivative positions, and the transaction summary shows no buys, sells, or other reportable trades.
EUDA Health Holdings Ltd director Huang Bo filed an initial statement of beneficial ownership as a new insider. This Form 3 filing does not report any share purchases, sales, or other transactions, and instead serves to formally register Huang Bo’s status as a reporting person for EUDA Health.
EUDA Health Holdings Limited updated its corporate charter and removed a potential source of new shares. The company adopted an Amended and Restated Memorandum and Articles of Association that, among other changes, expressly allows its board or shareholders to divide or combine ordinary shares by resolution.
EUDA also repurchased for US$125,000 and cancelled a warrant previously issued to Streeterville Capital, LLC that had been immediately exercisable for up to 2,000,000 ordinary shares. The warrant is no longer outstanding, and the potential share issuance under this agreement has been fully eliminated.
EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.
Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.
EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.
EUDA Health Holdings Limited reported that it has entered into a second amendment to its warrant agreement with Streeterville Capital, LLC. The amendment, dated January 13, 2026, reduces the warrant exercise price from US$4.00 per share to US$2.00 per share and lowers the minimum closing price required to trigger a forced exercise from US$6.00 to US$3.00. All other warrant terms remain unchanged.
EUDA’s Chief Executive Officer, Alfred Lim, described the change as a technical adjustment intended to align the warrant terms with current market conditions and preserve flexibility in the company’s capital structure, while emphasizing that it does not alter EUDA’s long-term strategy or operational priorities in preventive and longevity-focused healthcare.